Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 30.7% in January

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 597,300 shares, a growth of 30.7% from the December 31st total of 457,100 shares. Currently, 22.4% of the shares of the company are sold short. Based on an average trading volume of 421,900 shares, the days-to-cover ratio is currently 1.4 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Aligos Therapeutics in a report on Thursday, November 7th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ALGS. Drive Wealth Management LLC acquired a new position in shares of Aligos Therapeutics during the fourth quarter valued at $916,000. Golden State Wealth Management LLC acquired a new position in Aligos Therapeutics during the 4th quarter valued at about $107,000. Finally, AlphaMark Advisors LLC raised its position in shares of Aligos Therapeutics by 1,000.0% during the 4th quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock worth $44,000 after buying an additional 1,000 shares in the last quarter. 60.43% of the stock is owned by institutional investors and hedge funds.

Aligos Therapeutics Trading Up 8.7 %

NASDAQ ALGS traded up $2.06 during trading hours on Friday, reaching $25.80. The company’s stock had a trading volume of 374,497 shares, compared to its average volume of 301,097. The stock has a market cap of $92.62 million, a PE ratio of -1.94 and a beta of 2.50. The business has a 50-day simple moving average of $32.67 and a 200 day simple moving average of $19.10. Aligos Therapeutics has a 52 week low of $6.76 and a 52 week high of $46.80.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($3.07) EPS for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92). The company had revenue of $1.27 million for the quarter, compared to the consensus estimate of $1.00 million. Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. During the same quarter in the previous year, the company earned ($10.25) earnings per share. As a group, equities analysts predict that Aligos Therapeutics will post -10.36 EPS for the current year.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).